TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Rick Pierce
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Salarius Pharmaceuticals will rebrand as Decoy Therapeutics in early January 2026, reflecting a strategic pivot to a platform-driven biotechnology company focused on peptide-conjugate therapeutics targeting viral diseases and oncology.

Insights
SLRX   neutral

Undergoing corporate transformation through merger, maintaining existing operations while shifting strategic focus